PCRX
Pacira BioSciences, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$24.69
+0.86%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$24.40
From 52W high−10.61%
Volume650538.00
Market cap$984.19M
P/E (TTM)70.1x
P/S (TTM)1.3x
Div yield—
Key dataSep 18, 2026
Open
$24.40
From 52W high
−10.61%
Volume
650538.00
Market cap
$984.19M
ValuationView details →
P/E (Fwd)
8.1x
EV/EBITDA
10.0x
P/E (TTM)
70.1x
RSI (14)
43.7
MomentumView details →
1D Return
+0.86%
YTD Return
−5.29%
SummaryUpdated Jun 1, 2026
Pacira BioSciences, Inc. (NASDAQ:PCRX) is a Tampa, Florida-based specialty pharmaceutical company founded in 2006 that focuses on developing and commercializing non-opioid pain management and regenerative health solutions. Originally incorporated as Pacira Pharmaceuticals, the company rebranded to Pacira BioSciences in April 2019 to reflect its expanded focus beyond traditional pharmaceuticals into innovative biotechnology solutions. The company went public in February 2011 and has established itself as a leader in the non-opioid pain management space, addressing the critical need for alternatives to opioid-based treatments in surgical and chronic pain settings.
Similar companies
Latest newsMore news →
Pacira BioSciences reported second quarter 2026 total revenue of $192.4 million, a 6 percent year-over-year increase, and highlighted continued execution of its 5x30 strategy with solid revenue growth, durable cashflows, advancing pipeline, and commercial partnerships.47d agoUnitedHealthcare now provides separate reimbursement for Pacira BioSciences' EXPAREL across outpatient settings.81d agoPacira BioSciences agreed to divest its Pacira CryoTech subsidiary and related cryoanalgesia device assets to Zimmer, Inc. for up to $140 million.83d ago